Canadian Cancer Trials Group Bulletins


PR.3 in the News ... Again!

Interim results of Canadian Cancer Trials Group PR.3 -- Intergroup Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Adenocarcinoma of the Prostate -- show that combining radiation and hormone therapy in patients with high risk prostate cancer significantly improves the likelihood of patients living longer.

You may recall that Dr. Padraig Warde, the trial chair, presented these results in an oral presentation during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

We are very pleased to inform you these interim results were also just published in The Lancet on 3 November 2011 ( and has once again been the subject of quite a bit of media coverage both here in Canada and in the UK.

Here are some samples:

Stay tuned for results of the final analysis ...

We would like to extend our congratulations and appreciation to all participating centres, staff and patients in North America and the UK for all of their collaborative efforts in making this trial such a success. We expect these results will have a significant impact on the lives of men with high risk prostate cancer.